AMT-151 in Patients With Selected Advanced Solid Tumours
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05498597 |
Recruitment Status :
Recruiting
First Posted : August 12, 2022
Last Update Posted : October 19, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Advanced Solid Tumor Advanced Cancer Advanced Carcinoma Ovarian Cancer Ovarian Carcinoma Ovarian Epithelial Cancer Ovarian Endometrioid Adenocarcinoma Endometrial Cancer Endometrial Adenocarcinoma Endometrial Serous Adenocarcinoma Endometrial Endometrioid Adenocarcinoma Endometrial Clear Cell Adenocarcinoma Lung Adenocarcinoma Triple Negative Breast Cancer Pancreatic Ductal Adenocarcinoma Malignant Pleural Mesothelioma Ovarian Clear Cell Carcinoma Ovarian Clear Cell Adenocarcinoma Ovarian Mucinous Adenocarcinoma | Drug: AMT-151 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours |
Actual Study Start Date : | January 25, 2023 |
Estimated Primary Completion Date : | January 1, 2024 |
Estimated Study Completion Date : | October 30, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: AMT-151 Dose Escalation |
Drug: AMT-151
Administered intravenously |
- Recommended Phase 2 Dose (RP2D) [ Time Frame: Up to 24 months ]The RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data
- Maximum Tolerated Dose (MTD) [ Time Frame: Up to 24 months ]The MTD will be determined using DLTs
- Incidence of Adverse Events [ Time Frame: Up to 24 months ]Safety and tolerability profile assessed by the Common Terminology Criteria for Adverse Events v5.0
- Overall Response Rate (ORR) according to the Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 [ Time Frame: Up to 24 months ]Proportion of patients achieving Complete Response (CR) or Partial Response (PR)
- Disease Control Rate (DCR) according to the RECIST v1.1 [ Time Frame: Up to 24 months ]Proportion of patients achieving CR, PR or Stable Disease (SD)
- Progression-free Survival (PFS) [ Time Frame: Up to 24 months ]Time from date of start of treatment to date of the first progression or death, whichever occurs first.
- Time to Treatment Response (TTR) [ Time Frame: Up to 24 months ]Time from date of start of treatment to date of the first assessment of response (PR or CR)
- Duration of Response (DoR) [ Time Frame: Up to 24 months ]Time from date of first assessment of response (CR or PR) to date of the first progression or death, whichever occurs first
- Overall Survival (OS) [ Time Frame: Up to 24 months ]Time from date of start of treatment to date of death
- Concentration of anti-drug antibodies (ADA) [ Time Frame: Up to 24 months ]Immunogenicity profile characterized by concentration of ADAs
- Maximum observed concentration (C[max]) [ Time Frame: Up to 24 months ]Pharmacokinetic profile characterized by the maximum observed concentration (C[max]) of AMT-151
- Area under the curve (AUC) [ Time Frame: Up to 24 months ]Pharmacokinetic profile characterized by the area under the curve (AUC) of AMT-151
- Terminal half-life (t[1/2]) [ Time Frame: Up to 24 months ]Pharmacokinetic profile characterized by the terminal half-life (t[1/2]) of AMT-151
- Time to maximum concentration (Tmax) [ Time Frame: Up to 24 months ]Pharmacokinetic profile characterized by the time to maximum concentration (Tmax) of AMT-151
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Patients must be willing and able to sign the Informed Consent Form, and to adhere to the study visit schedule and other protocol requirements.
- Age ≥18 years (at the time consent is obtained).
-
Patients with the following histologically confirmed, advanced cancer diagnoses:
- Serous, endometrioid, clear-cell, or mucinous epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Serous, endometrioid, or clear-cell endometrial cancer.
- Adenocarcinoma of the lung.
- Triple-negative breast cancer.
- Pancreatic ductal adenocarcinoma.
- Malignant pleural mesothelioma.
- Patients who have undergone any number of prior systemic therapies and have radiologically or clinically determined progressive disease during or after their most recent line of therapy, and for whom no further standard therapy is available, or who are intolerable to standard therapy.
- Patients must have at least one measurable or non-measurable lesion as per RECIST version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate function of bone marrow, liver, kidneys, heart.
- Both male and female patients must agree to use effective contraceptive methods.
- Women of child-bearing potential (WCBP) must have a negative serum pregnancy test.
- Availability of tumour tissue sample (either an archival specimen or a fresh biopsy material) at screening.
Key Exclusion Criteria:
- Prior treatment with any agent targeting Folate Receptor Alpha.
- Active central nervous system metastasis.
- Persistent toxicities from previous systemic anti-neoplastic treatments of Grade >1.
- Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to the first dose of the study drug.
- Radiotherapy to lung field at a total radiation dose of >= 20 Gy within 6 months, wide-field radiotherapy (>30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to the first dose of the study drug, or no recovery from side effects of such intervention.
- Major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to the first dose of the study drug, or no recovery from side effects of such intervention.
- Prior allogeneic or autologous bone marrow transplantation.
- Significant cardiac or lung disease, active or chronic ocular disorders, thromboembolic or cerebrovascular events within 6 months prior to the first dose of the study drug, acute and/or clinically significant bacterial, fungal, or viral infection.
- Pregnant or breast-feeding females.
Note: Other protocol defined Inclusion/Exclusion criteria apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05498597
Contact: Jane Zhu | 13917933915 | juanjuan.zhu@multitudetherapeutics.com |
Australia, New South Wales | |
Chris O'Brien Lifehouse | Recruiting |
Sydney, New South Wales, Australia | |
Contact: Steven Kao 61 02 8514 0140 | |
Australia, Queensland | |
ICON Cancer Centre | Recruiting |
Brisbane, Queensland, Australia | |
Contact: Jermaine Coward | |
Mater Cancer Care Centre | Recruiting |
South Brisbane, Queensland, Australia | |
Contact: Catherine Shannon | |
Australia, South Australia | |
Cancer Research SA | Recruiting |
Adelaide, South Australia, Australia | |
Contact: Sarwan Bishnoi 61 08 3592 565 | |
Australia, Victoria | |
Cabrini Malvern Hospital | Recruiting |
Malvern, Victoria, Australia | |
Contact: Richardson Gary 61 03 9508 9542 | |
Australia, Western Australia | |
One Clinical Research (OCR) | Recruiting |
Perth, Western Australia, Australia | |
Contact: Mihitha Ariyapperuma 61 08 6279 9466 | |
China, Fujian | |
Fujian Provincial Cancer Hospital | Not yet recruiting |
Fuzhou, Fujian, China, 350014 | |
Contact: An Lin, Director | |
China, Hunan | |
Hunan Cancer Hospital | Not yet recruiting |
Changsha, Hunan, China, 410031 | |
Contact: Jing Wang, Director 13875902083 wangjing0081@126.com | |
China, Shanghai | |
Shanghai Tumor Hospital | Not yet recruiting |
Shanghai, Shanghai, China, 200032 | |
Contact: Jian Zhang, Director 02164175590 syner2000@163.com | |
Contact: Xiaohua Wu, Director 15618369676 edison-1016@163.com |
Principal Investigator: | Sarwan Bishnoi | Cancer Research SA | |
Principal Investigator: | Richardson Gary | Cabrini Malvern Hospital | |
Principal Investigator: | Steven Kao | Chris O'Brien Lifehouse | |
Principal Investigator: | Catherine Shannon | Mater Cancer Care Centre | |
Principal Investigator: | Jermaine Coward | ICON Cancer Centre | |
Principal Investigator: | Mihitha Ariyapperuma | One Clinical Research (OCR) |
Responsible Party: | Multitude Therapeutics Inc. |
ClinicalTrials.gov Identifier: | NCT05498597 |
Other Study ID Numbers: |
AMT-151-01 |
First Posted: | August 12, 2022 Key Record Dates |
Last Update Posted: | October 19, 2023 |
Last Verified: | October 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma Cancer Antibody-Drug Conjugate Folate Receptor Alpha |
Carcinoma Adenocarcinoma Endometrial Neoplasms Triple Negative Breast Neoplasms Mesothelioma Mesothelioma, Malignant Carcinoma, Ovarian Epithelial Adenocarcinoma of Lung Cystadenocarcinoma, Serous Carcinoma, Endometrioid Adenocarcinoma, Clear Cell Adenocarcinoma, Mucinous Cystadenocarcinoma Adenomyoepithelioma Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Neoplasms Ovarian Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Ovarian Diseases Adnexal Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Neoplasms, Female Urogenital Neoplasms Genital Diseases Endocrine System Diseases |